Chemotherapy definitions and policies for thymic malignancies

Journal of Thoracic Oncology

Volumn 6, Issue 7 SUPPL. 3, 2011, Pages

  Girard, Nicolas ^a   Lal, Rohit ^b   Wakelee, Heather ^c   Riely, Gregory J ^d   Loehrer, Patrick J ^e  

^a HOSPICES CIVILS DE LYON   (France)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Corticosteroids; Octreotide; Radiotherapy; Thymic carcinoma; Thymic hyperplasia; Thymoma

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; OCTREOTIDE; PACLITAXEL; PEMETREXED; PREDNISONE; VINCRISTINE;

ARTICLE; BIOPSY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CARDIOVASCULAR RISK; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; HUMAN; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; THYMUS CANCER; THYMUS HYPERPLASIA; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 79959836108     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31821ea5f7     Document Type: Article

References (42)

1. Girard N, Mornex F, Van Houtte P, et al. Thymoma: a focus on current therapeutic management. J Thorac Oncol 2009;4:119-126.
2. Fornasiero A, Daniele O, Ghiotto C, et al. Chemotherapy of invasive thymoma. J Clin Oncol 1990;8:1419-1423. (Pubitemid 20252315)
3. Venuta F, Rendina EA, Longo F, et al. Long-term outcome after multimodality treatment for stage III thymic tumors. Ann Thorac Surg 2003;76:1866-1872. (Pubitemid 37510495)
4. Lucchi M, Ambrogi MC, Duranti L, et al. Advanced stage thymomas and thymic carcinomas: results of multimodality treatments. Ann Thorac Surg 2005;79:1840-1844. (Pubitemid 40804146)
5. Jacot W, Quantin X, Valette S, et al. Multimodality treatment program in invasive thymic epithelial tumor. Am J Clin Oncol 2005;28:5-7. (Pubitemid 40209316)
6. Rea F, Sartori F, Loy M, et al. Chemotherapy and operation for invasive thymoma. J Thorac Cardiovasc Surg 1993;106:543-549. (Pubitemid 23277629)
7. Bretti S, Berruti A, Loddo C, et al. Multimodal management of stages III-IVa malignant thymoma. Lung Cancer 2004;44:69-77. (Pubitemid 38317263)
8. Yokoi K, Matsuguma H, Nakahara R, et al. Multidisciplinary treatment for advanced invasive thymoma with cisplatin, doxorubicin, and methylprednisolone. J Thorac Oncol 2007;2:73-78. (Pubitemid 47163933)
9. Wright CD, Choi NC, Wain JC, et al. Induction chemoradiotherapy followed by resection for locally advanced Masaoka stage III and IVA thymic tumors. Ann Thorac Surg 2008;85:385-389.
10. Loehrer PJ Sr, Kim K, Aisner SC, et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol 1994;12:1164-1168. (Pubitemid 24173929)
11. Giaccone G, Ardizzoni A, Kirkpatrick A, et al. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1996;14:814-820.
12. Loehrer PJ Sr, Jiroutek M, Aisner S, et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer 2001;91: 2010-2015. (Pubitemid 32476364)
13. Lemma GL, Loehrer PJ, Lee JW, et al. A phase II study of carboplatin plus paclitaxel in advanced thymoma or thymic carcinoma: E1C99. J Clin Oncol 2008;26:8018.
14. Macchiarini P, Chella A, Ducci F, et al. Neoadjuvant chemotherapy, surgery, and postoperative radiation therapy for invasive thymoma. Cancer 1991;68:706-713.
15. Kim ES, Putnam JB, Komaki R, et al. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer 2004;44:369-379. (Pubitemid 38609446)
16. Berruti A, Borasio P, Roncari A, et al. Neoadjuvant chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide (ADOC) in invasive thymomas: results in six patients. Ann Oncol 1993;4:429-431. (Pubitemid 23193111)
17. Kunitoh H, Tamura T, Shibata T, et al. A phase II trial of dose-dense chemotherapy, followed by surgical resection and/or thoracic radiotherapy, in locally advanced thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9606). Br J Cancer 2010;103:6-11.
18. Loehrer PJ Sr, Chen M, Kim K, et al. Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. J Clin Oncol 1997;15:3093-3099. (Pubitemid 27377501)
19. Berruti A, Borasio P, Gerbino A, et al. Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience. Br J Cancer 1999; 81:841-845. (Pubitemid 29504694)
20. Bonomi PD, Finkelstein D, Aisner S, Ettinger D. EST 2582 phase II trial of cisplatin in metastatic or recurrent thymoma. Am J Clin Oncol 1993;16:342-345. (Pubitemid 23217895)
21. Highley MS, Underhill CR, Parnis FX, et al. Treatment of invasive thymoma with single-agent ifosfamide. J Clin Oncol 1999;17:2737-2744. (Pubitemid 29415230)
22. Huang J, Detterbeck F, Wang Z, et al. Standard outcome measures for thymic malignancies. J Thorac Oncol 2010;5:2017-2023.
23. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984;2:1281-1288. (Pubitemid 15202705)
24. http://evs.nci.nih.gov/ftp1/CTCAE. Accessed December 31, 2010.
25. Mygland A, Vincent A, Newsom-Davis J, et al. Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia. Arch Neurol 2000;57:527-531. (Pubitemid 30212127)
26. Loehrer PJ Sr, Wang W, Johnson DH, et al.; Eastern Cooperative Oncology Group Phase II Trial. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol 2004;22:293-299. (Pubitemid 41095094)
27. Tormoehlen LM, Pascuzzi RM. Thymoma, myasthenia gravis, and other paraneoplastic syndromes. Hematol Oncol Clin North Am 2008;22:509-526. (Pubitemid 351726408)
28. Detterbeck F, Nicholson AG, Kondo K, et al. The Masaoka-Koga Stage Classification for thymic malignancies: clarification and definition of terms. J Thorac Oncol. 2011;6:S1710-S1716.
29. Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg 2003;76:878-884. (Pubitemid 37100765)
30. Gomez D, Komaki R, Yu J, et al. Radiation therapy definitions and reporting guidelines for thymic malignancies. J Thoracic Oncol. 2011;6: S1743-S1748.
31. Cowen D, Richaud P, Mornex F, et al. Thymoma: results of a multicentric retrospective series of 149 non-metastatic irradiated patients and review of the literature. FNCLCC trialists. Fédération Nationale des Centres de Lutte Contre le Cancer. Radiother Oncol 1995;34:9-16.
32. Shin DM, Walsh GL, Komaki R, et al. A multidisciplinary approach to therapy for unresectable malignant thymoma. Ann Intern Med 1998;129: 100-104. (Pubitemid 28337251)
33. Eng TY, Fuller CD, Jagirdar J, et al. Thymic carcinoma: state of the art review. Int J Radiat Oncol Biol Phys 2004;59:654-664. (Pubitemid 38748730)
34. Loehrer PJ, Yiannoutsos CT, Dropcho S, et al. A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma. J Clin Oncol 2006;24:7079.
35. Kirkove C, Berghmans J, Noel H, et al. Dramatic response of recurrent invasive thymoma to high doses of corticosteroids. Clin Oncol (R Coll Radiol) 1992;4:64-66.
36. Craven C, Reddy PK, Ringel SP, et al. Effect of corticosteroids on the thymus in myasthenia gravis. Muscle Nerve 1981;4:425-428. (Pubitemid 11004279)
37. Gerhardt S, Gehling G, Schuster P. Rebound hyperplasia of the thymus with secondary intrathymic bleeding. Rare differential diagnosis of acute chest pain. Dtsch Med Wochenschr 2004;129:1916-1918. (Pubitemid 39233512)
38. Miniero R, Busca A, Leonardo E, et al. Rebound thymic hyperplasia following high dose chemotherapy and allogeneic BMT. Bone Marrow Transplant 1993;11:67-70. (Pubitemid 23086850)
39. Hendrickx P, Döhring W. Computed tomographic detection of chemotherapy- induced thymus changes in patients with metastatic testicular tumors. Rofo 1989;150:268-273. (Pubitemid 19082233)
40. Nishino M, Ashiku S, Kocher ON, et al. The thymus: a comprehensive review. Radiographics 2005;26:325-348.
41. Kumar A, Regmi SK, Dutta R, et al. Characterization of thymic masses using (18)F-FDG PET-CT. Ann Nucl Med 2009;23:569-577.
42. Takahashi K, Inaoka T, Murakami N, et al. Characterization of the normal and hyperplastic thymus on chemical-shift MR imaging. AJR Am J Roentgenol 2003;180:1265-1269. (Pubitemid 36504612)